Daclatasvir and Asunaprevir Combination Therapy-induced Hepatitis and Cholecystitis with Coagulation Disorder Due to Hypersensitivity Reactions

Overview

Journal Intern Med

Specialty General Medicine

Date 2016 Dec 17

PMID 27980259

Citations 2

Authors

Yuichi Miyashima

Yuichi Honma

Koichiro Miyagawa

Shinji Oe

Michio Senju

Michihiko Shibata

Masaaki Hiura

Shintaro Abe

Masaru Harada

Affiliations

Soon will be listed here.

Abstract

A 70-year-old woman with chronic hepatitis C was admitted to our hospital due to liver injury, cholecystitis, and disseminated intravascular coagulation with a fever and skin rash. She had been on a combination regimen of daclatasvir and asunaprevir for 2 weeks of a 24-week regimen. Because of the symptoms, laboratory findings, results of a drug-induced lymphocyte stimulation test, and pathological findings of liver biopsy, we diagnosed her with drug-induced liver injury. Although daclatasvir and asunaprevir combination therapy is generally well-tolerated, some serious adverse effects have been reported. Our findings indicate that immunoallergic mechanisms were associated with daclatasvir and asunaprevir-induced liver injury.

Citing Articles

Use of In Vivo Imaging and Physiologically-Based Kinetic Modelling to Predict Hepatic Transporter Mediated Drug-Drug Interactions in Rats.

Melillo N, Scotcher D, Kenna J, Green C, Hines C, Laitinen I Pharmaceutics. 2023; 15(3).

PMID: 36986758 PMC: 10057977. DOI: 10.3390/pharmaceutics15030896.

Recent Advances in the Histopathology of Drug-Induced Liver Injury.

Kleiner D Surg Pathol Clin. 2018; 11(2):297-311.

PMID: 29751876 PMC: 5953206. DOI: 10.1016/j.path.2018.02.009.

References

Figtree M, Miyakis S, Tanaka K, Martin L, Konecny P, Krilis S . Dapsone hypersensitivity syndrome causing disseminated intravascular coagulation. BMJ Case Rep. 2011; 2009. PMC: 3030115. DOI: 10.1136/bcr.11.2008.1257. View

Qin X, Gao B . The complement system in liver diseases. Cell Mol Immunol. 2006; 3(5):333-40. View

Cacoub P, Bourliere M, Lubbe J, Dupin N, Buggisch P, Dusheiko G . Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol. 2011; 56(2):455-63. DOI: 10.1016/j.jhep.2011.08.006. View

CHAIKEN B, Goldberg B, Segal J . Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med. 1950; 242(23):897-8. DOI: 10.1056/NEJM195006082422304. View

Ellison 3rd R, Horsburgh Jr C, Curd J . Complement levels in patients with hepatic dysfunction. Dig Dis Sci. 1990; 35(2):231-5. DOI: 10.1007/BF01536768. View

Manns M, Pol S, Jacobson I, Marcellin P, Gordon S, Peng C . All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014; 384(9954):1597-605. DOI: 10.1016/S0140-6736(14)61059-X. View

Fujii Y, Uchida Y, Mochida S . Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir. Hepatology. 2014; 61(1):400-1. DOI: 10.1002/hep.27559. View

Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K . Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2012; 58(4):655-62. DOI: 10.1016/j.jhep.2012.09.037. View

Takikawa H, Takamori Y, Kumagi T, Onji M, Watanabe M, Shibuya A . Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting. Hepatol Res. 2003; 27(3):192-195. DOI: 10.1016/s1386-6346(03)00232-8. View

10.

Singhal R, Ganey P, Roth R . Complement activation in acetaminophen-induced liver injury in mice. J Pharmacol Exp Ther. 2012; 341(2):377-85. PMC: 3336815. DOI: 10.1124/jpet.111.189837. View

11.

Shiohara T, Inaoka M, Kano Y . Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int. 2006; 55(1):1-8. DOI: 10.2332/allergolint.55.1. View

12.

Michielsen P, Fierens H, Van Maercke Y . Drug-induced gallbladder disease. Incidence, aetiology and management. Drug Saf. 1992; 7(1):32-45. DOI: 10.2165/00002018-199207010-00005. View

13.

Biesbroeck L, Scott J, Taraska C, Moore E, Falsey R, Shinohara M . Direct-acting antiviral-associated dermatitis during chronic hepatitis C virus treatment. Am J Clin Dermatol. 2013; 14(6):497-502. DOI: 10.1007/s40257-013-0035-7. View

14.

Kano Y, Shiohara T . The variable clinical picture of drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms in relation to the eliciting drug. Immunol Allergy Clin North Am. 2009; 29(3):481-501. DOI: 10.1016/j.iac.2009.04.007. View

15.

Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K . Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014; 59(6):2083-91. PMC: 4315868. DOI: 10.1002/hep.27113. View

16.

Tajiri K, Shimizu Y . Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol. 2008; 14(44):6774-85. PMC: 2773872. DOI: 10.3748/wjg.14.6774. View

17.

Verma S, Kaplowitz N . Diagnosis, management and prevention of drug-induced liver injury. Gut. 2009; 58(11):1555-64. DOI: 10.1136/gut.2008.163675. View

18.

Mona Ben Mrad , Leclerc-Mercier S, Blanche P, Franck N, Rozenberg F, Fulla Y . Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore). 2009; 88(3):131-140. DOI: 10.1097/MD.0b013e3181a4d1a1. View

19.

Kimura Y, Takada T, Strasberg S, Pitt H, Gouma D, Garden O . TG13 current terminology, etiology, and epidemiology of acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2013; 20(1):8-23. DOI: 10.1007/s00534-012-0564-0. View